Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.
MLTX Stock Jumps Over 10% Overnight As Spine Drug Trial Win Sets Stage For Investor Day Showdown Investors are now turning to Monday’s Investor Day for regulatory clarity, pipeline updates, and key 2026 catalysts.
MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week The investor day update comes after a stock collapse last year following mixed Phase 3 VELA trial results that raised concerns about approval risk.
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event Some Stocktwits users voiced optimism for the inflammation-drug maker getting acquired by pharma giant Merck.
MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab The FDA said that the drug, which treats a chronic inflammatory skin disorder, could establish evidence without additional trials.
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation MoonLake Immunotherapeutics (
NASDAQ: MLTX ) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its lead drug candidate, sonelokimab. The Swiss biotech company announced on January 8, 2026, that a successful Type B meeting with the U.
Why Did MLTX Stock Jump 45% In Pre-Market Today? The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder.
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next.
The Best AI for Picking Stocks, Ranked by Performance AI can pick stocks, but that doesn't mean it will do a good job. Here's a look at how the choices made by 7 leading AIs performed over a 90-day time period.
Which stocks have an unusual volume on Monday? Volume analysis on 2025-10-06: stocks with an unusual volume in today's session.
Unusual volume stocks are being observed in Friday's session. In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
